At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 154 enrolled
Drug / intervention
Dapagliflozin +2 moredrug
Likely dose
Dapagliflozin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Phase 2 Study to Assess the Effect of Dapagliflozin on Glomerular Filtration Rate (GFR) in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic and Blood Pressure (BP) Control
In Brief
A Phase 2 clinical trial evaluating Dapagliflozin, Placebo, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 154 participants across 12 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the effects of dapagliflozin on kidney function, as assessed by glomerular filtration rate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesCanada, Netherlands, United States
CollaboratorsAstra Zeneca, Bristol-Myers Squibb
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartOct 2009
Primary CompletionNov 2010
TodayJul 2026
First PostedSep 14, 2009
Enrollment StartOct 1, 2009
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.8 years ago
Interventions
Dapagliflozindrug
Tablets, Oral, 10 mg, once daily, 12 weeks
Placebodrug
Tablets, Oral, 0 mg, once daily, 12 weeks
Hydrochlorothiazidedrug
Tablets, Oral, 25 mg, once daily, 12 weeks